Sevilay SEZER, Fatma UÇAR, Ersin Kasım ULUSOY, Serpil ERDOĞAN, Şule BİLEN, Cevdet ZÜNGÜN, Sema UYSAL, Hacı Kemal ERDEMLİ

Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers?

Inflammation plays an important role in acute ischemic stroke. In this study we aimed to investigate the relationship between acute ischemic stroke and serum amyloid A, fetuin-A, and pentraxin-3 which are inflammation markers. Materials and methods: We enrolled 52 patients with acute ischemic stroke and 30 sex-matched control subjects in the study. The patients were followed for 3 months. We evaluated the common risk factors, laboratory variables, and neurological examination of stroke patients according to prognosis scales. Results: The median serum amyloid A, fetuin-A, and pentraxin-3 levels in the stroke patients were higher than in control subjects (respectively, P = 0.000, P = 0.002, and P = 0.037). National Institutes of Health Stroke Scale scores, glucose, C-reactive protein, fibrinogen, and white blood cell count showed differences within the group in terms of the serum amyloid A tertiles statistically. Conclusion: Pentraxin-3, fetuin-A, and serum amyloid A all arise together as novel prognostic factors in a group of patients with ischemic stroke. Relationships between higher levels of inflammation markers, especially serum amyloid A, and the severity of acute ischemic stroke were shown.

Anahtar Kelimeler:

fetuin-A, pentraxin-3, acute ischemic stroke, Serum amyloid A

Serum amyloid A, fetuin-A, and pentraxin-3 levels in patients with ischemic stroke: novel prognostic biomarkers?

Keywords:

fetuin-A, pentraxin-3, acute ischemic stroke, Serum amyloid A,

PDF

___

Ormstad H, Aass HCD, Lund-Sİrensen N, Amthor KF, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol 2011; 258: 677–685.
den Hertog HM, van den Herik EG, Dippel DW, Koudstaal PJ, de Maat MP. Variation in the C-reactive protein gene is associated with serum levels of CRP in patients with acute ischemic stroke. Cerebrovasc Dis 2010; 29: 372–375.
Song IU, Kim JS, Kim YI, Lee KS, Jeong DS, Chung SW. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009; 28: 545–550.
Tuttolomondo A, Di Raimondo D, Di Sciacca R, Casuccio A, Bivona G, Bellia C, Barreca L, Serio A, D’Aguanno G, Ciaccio M et al. Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis 2010; 208: 290–296.
Brea D, Sobrino T, Blanco M, Fraga M, Agulla J, Rodríguez- Yáñez M, Rodríguez-González R, Pérez de la Ossa N, Leira R, Forteza J et al. Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. Atherosclerosis 2009; 205: 561–567.
Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501–523.
Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726–732.
Idicula TT, Waje-Andreassen U, Brogger J, Naess H, Thomassen L. Serum albumin in ischemic stroke patients: the higher the better. Cerebrovasc Dis 2009; 28: 13–17.
Chen PH, Gao S, Wang YJ, Xu AD, Li YS, Wang D. Classifying ischemic stroke, from TOAST to CISS. CNS Neurosci Ther 2012; 18: 452–456.
Sunnerhagen KS, Olver J, Francisco GE. Assessing and treating functional impairment in poststroke spasticity. Neurology 2013; 80: 35–44.
Somford DM, Marks MP, Thijs VN, Tong DC. Association of early CT abnormalities, infarct size, and apparent diffusion coefficient reduction in acute ischemic stroke. Am J Neuroradiol 2004; 25: 933–938.
Xu C, Yi C, Guo H, Liu Q, Wang L, Li H. Limb remote ischemic postconditioning is effective but also time-course-limited in protecting the brain from I/R injury. Turk J Med Sci 2012; 42: 918–929.
Vila N, Castillo J, Dávalos A, Chamorro Á. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325–2329.
Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic- Ivanovic Z, Bogavac-Stanojevic N, Gulan B, Spasic S. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010; 210: 548–554.
Süt N, Çelik Y. Prediction of mortality in stroke patients using multilayer perceptron neural networks. Turk J Med Sci 2012; 42: 886–893.
Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010; 87: 779– 789.
Kisialiou A, Pelone G, Carrizzo A, Grillea G, Trimarco V, Marino M, Bartolo M, De Nunzio AM, Grella R, Landolfi A et al. Blood biomarkers role in acute ischemic stroke patients: higher is worse or better? Immun Ageing 2012; 9: 22.
Kumar AD, Boehme AK, Siegler JE, Gillette M, Albright KC, Martin-Schild S. Leukocytosis in patients with neurologic deterioration after acute ischemic stroke is associated with poor outcomes. J Stroke Cerebrovasc Dis 2013; 22: e111–e117.
Rallidis LS, Vikelis M, Panagiotakos DB, Rizos I, Zolindaki MG, Kaliva K, Kremastinos DT. Inflammatory markers and in- hospital mortality in acute ischaemic stroke. Atherosclerosis 2006; 189: 193–197.
den Hertog HM, van Rossum JA, van der Worp HB, van Gemert HM, de Jonge R, Koudstaal PJ, Dippel DW. C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J Neurol 2009; 256: 2003–2008.